2019
DOI: 10.1097/mco.0000000000000600
|View full text |Cite
|
Sign up to set email alerts
|

Fatty acid-binding proteins

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
14
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 33 publications
(16 citation statements)
references
References 68 publications
1
14
0
Order By: Relevance
“…In the last synthesis step, acylation with stearic acid was carried out in order to introduce a hydrophobic end group to the molecule. This end group allows for locating the polymer drug conjugate close to cell membranes . To investigate the influence of the PEG chain length on the behavior of our structures, we further synthesized oligopeptoids containing polymeric PEG with a molecular weight of 2000 g mol –1 as side chains.…”
Section: Introductionmentioning
confidence: 99%
“…In the last synthesis step, acylation with stearic acid was carried out in order to introduce a hydrophobic end group to the molecule. This end group allows for locating the polymer drug conjugate close to cell membranes . To investigate the influence of the PEG chain length on the behavior of our structures, we further synthesized oligopeptoids containing polymeric PEG with a molecular weight of 2000 g mol –1 as side chains.…”
Section: Introductionmentioning
confidence: 99%
“…Under physiological conditions, CD36 expression is low in hepatocytes, but CD36 is highly induced with lipid overload and is activated by transcription factors ( 26 ). Once FFAs enter hepatocytes, they are bound and transported by fatty acid binding protein 1 (FABP1), and functional PPREs identified within the FABP1 promoter are regulated by PPARα based on nutritional conditions through protein–protein interactions ( 15 , 27 29 ). Carnitine palmitoyltransferase 1A (CPT1A), which transports FFAs into mitochondria, is localized in the outer mitochondrial membrane and acts as a β-oxidation rate-limiting enzyme regulated by PPARα ( 15 , 30 ).…”
Section: Introductionmentioning
confidence: 99%
“…Protein engineering refers to the process of optimizing protein sequences for enhanced physical (e.g., thermal stability, solubility, and complex stoichiometry), chemical (e.g., reactivity, substrate specificity, selectivity, and substrate scope), biological, and pharmaceutical functions. Typical strategies in protein engineering include directed evolution, gene shuffling/recombination, , site-directed mutagenesis, , and protein truncation and fusion. , Enabled by protein engineering, researchers can create enzymes to accelerate low-efficiency or even new-to-nature reactions, , develop peptides with targeted therapeutic effects, , innovate diagnostic tools for early stage cancer detection, and advance our understanding of fundamental life processes. , …”
Section: Introductionmentioning
confidence: 99%